Article
Developing live<i>Shigella</i>vaccines using λ Red recombineering
9 Jun 2006
Abstract excerpt
Live attenuated Shigella vaccines have shown promise in inducing protective immune responses in human clinical trials and as carriers of heterologous antigens from other mucosal pathogens. In the past, construction of Shigella vaccine strains relied on classical allelic exchange systems to genetically engineer the bacterial genome. These systems require extensive in vitro engineering of long homologous sequences...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
